protein

TFRC

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about TFRC: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

381Connections

2Hypotheses

2Analyses

50Outgoing

50Incoming

9Experiments

2Debates

Summary

TFRC is a protein involved in neurodegeneration research. Key relationships include: associated with, activates, regulates. Associated with ALS, Als, Atherosclerosis. Connected to 134 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🔬 Protein Info

Gene Symbol	TFRC
Full Name	Transferrin Receptor 1
Chromosome	3q29
Protein Type	Receptor
Target Class	Receptor
Function	Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake
Mechanism of Action	Monoclonal antibodies targeting receptor or iron chelation affecting iron uptake
Druggability	Medium (0.47)
Clinical Stage	Approved
Molecular Weight	190 kDa
Amino Acids	660 aa
Pathways	Akt, Autophagy, Blood-Brain Barrier, Ferroptosis, Pi3K
UniProt ID	P02786
NCBI Gene ID	7037
Ensembl ID	ENSG00000072274
GeneCards	TFRC
Human Protein Atlas	TFRC
Associated Diseases	Als, ALZHEIMER, Atherosclerosis, Diabetes, Inflammation
Known Drugs/Compounds	Adeno-Associated Virus, Antisense Oligonucleotides, rapamycin, resveratrol
Interactions	ACSL4, ACTB, ALZHEIMER, ALZHEIMER'S DISEASE, AND, APOPTOSIS
SciDEX Target	View Target Profile (8 clinical trials)
SciDEX Hypotheses	Blood-Brain Barrier SPM Shuttle System Transferrin-Alectinib Conjugation Enhances Blood-B
KG Connections	380 knowledge graph edges
Databases	GeneCards HPA STRING

🧬 3D Structure Comparison — TFRC Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

1CX8 — X-ray / Cryo-EM

🔮 AI Predicted Structure

P02786 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (3)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

graph TD
    TFRC["TFRC"]
    TFRC -->|"interacts"| Ms["Ms"]
    TFRC -->|"interacts"| Parkinson["Parkinson"]
    TFRC -->|"target for"| Inflammation["Inflammation"]
    TFRC -->|"activates"| Als["Als"]
    h_959a4677["h-959a4677"] -->|"target for"| TFRC
    JUN["JUN"] -->|"interacts"| TFRC
    TFR1["TFR1"] -->|"expressed in"| TFRC
    GBA1["GBA1"] -->|"interacts"| TFRC
    GENES["GENES"] -->|"interacts"| TFRC
    PI3K["PI3K"] -->|"regulates"| TFRC
    AKT["AKT"] -->|"regulates"| TFRC

Outgoing (182)

Target	Relation	Type	Str
Ferroptosis	biomarker_for	process	0.95
Transferrin Receptor 1	encodes	protein	0.95
blood-brain barrier	mediates	brain_region	0.95
Transferrin Receptor 1	associated_with	protein	0.95
blood-brain barrier	associated_with	brain_region	0.95
Ferroptosis And Iron Metabolism	involved_in	process	0.95
antisense oligonucleotides	mediates	drug	0.95
Antisense Oligonucleotides	binds	drug	0.95
Adeno-Associated Virus	binds	compound	0.95
ferroptotic cells	associated_with	cell_type	0.92
central nervous system	associated_with	brain_region	0.92
Ferroptosis	involved_in	process	0.90
Brain Penetration	mediates	process	0.90
iron	binds	compound	0.90
iron metabolism	regulates	process	0.90
iron	mediates	compound	0.90
transcytosis	involved_in	process	0.90
Ferroptosis	correlates_with	process	0.90
Iron Metabolism	involved_in	process	0.90
endocytosis	mediates	process	0.85
Iron Uptake	involved_in	process	0.85
Amyloid-Related Imaging Abnormalities	protects_against	phenotype	0.85
BACE1	co_expressed_with	protein	0.80
amyloid-beta	regulates	protein	0.80
ferroptosis	promotes	process	0.80
transferrin_receptor	encodes	protein	0.80
Als	activates	disease	0.75
Autophagy	associated_with	pathway	0.70
Ferroptosis	associated_with	pathway	0.70
Apoptosis	activates	pathway	0.70
neurodegeneration	associated_with	disease	0.66
Als	regulates	disease	0.65
Ms	regulates	disease	0.65
Parkinson	therapeutic_target	disease	0.65
Als	associated_with	disease	0.65
Inflammation	therapeutic_target	disease	0.65
Ms	activates	disease	0.65
Ms	interacts_with	disease	0.65
Parkinson	interacts_with	disease	0.65
Diabetes	associated_with	disease	0.65
Ms	associated_with	disease	0.65
Atherosclerosis	associated_with	disease	0.65
Alzheimer	inhibits	disease	0.65
Ferroptosis	expressed_in	disease	0.65
Als	expressed_in	disease	0.65
Cancer	inhibits	disease	0.65
Ms	expressed_in	disease	0.65
Colorectal Cancer	activates	disease	0.65
Cancer	activates	disease	0.65
Tumor	activates	disease	0.65

Incoming (199)

Source	Relation	Type	Str
h-959a4677	targets_gene	hypothesis	0.90
Chronic cerebral hypoperfusion	upregulates	process	0.85
Cadmium	upregulates	compound	0.80
h-959a4677	targets	hypothesis	0.80
BID	expressed_in	gene	0.60
EGFR	associated_with	gene	0.60
IL1B	associated_with	gene	0.60
EGFR	regulates	gene	0.60
GPX4	regulates	gene	0.60
IL1B	regulates	gene	0.60
SLC7A11	regulates	gene	0.60
resveratrol	targets	drug	0.60
PSME3	expressed_in	gene	0.60
FERROPTOSIS	expressed_in	gene	0.60
APOPTOSIS	expressed_in	gene	0.60
PARKINSON	therapeutic_target	gene	0.60
AUTOPHAGY	expressed_in	gene	0.60
MTOR	expressed_in	gene	0.60
rapamycin	targets	drug	0.60
MTOR	activates	gene	0.60
NBR1	activates	gene	0.60
NFE2L2	activates	gene	0.60
NOX1	activates	gene	0.60
OPTN	activates	gene	0.60
PPARGC1A	activates	gene	0.60
SIRT1	activates	gene	0.60
SQSTM1	activates	gene	0.60
TFEB	activates	gene	0.60
GENES	interacts_with	gene	0.60
GENES	therapeutic_target	gene	0.60
DNA	activates	gene	0.60
AND	associated_with	gene	0.60
APOPTOSIS	associated_with	gene	0.60
IFN-Γ	therapeutic_target	gene	0.60
IFN	therapeutic_target	gene	0.60
IL-1	therapeutic_target	gene	0.60
IL-17	therapeutic_target	gene	0.60
IFN	associated_with	gene	0.60
IFN-Γ	associated_with	gene	0.60
NADPH	activates	gene	0.60
NFKB	activates	gene	0.60
P21	activates	gene	0.60
JUN	interacts_with	gene	0.60
TFR1	expressed_in	gene	0.60
GBA1	interacts_with	gene	0.60
LAMP2	associated_with	gene	0.60
MTOR	associated_with	gene	0.60
GBA1	regulates	gene	0.60
BID	associated_with	gene	0.60
PPP1CB	associated_with	gene	0.60

Targeting Hypotheses (2)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
Blood-Brain Barrier SPM Shuttle System	0.533	neurodegeneration	Neuroinflammation resolution mechanisms
Transferrin-Alectinib Conjugation Enhances Blood-Brain Barri	0.406	molecular biology	Does Alectinib truly bind C1q directly w

Mentioning Analyses (2)

Scientific analyses that reference this entity

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

neurodegeneration | 2026-04-03 | 18 hypotheses Top: 0.847

Neuroinflammation resolution mechanisms and pro-resolving mediators

neurodegeneration | 2026-04-01 | 7 hypotheses Top: 0.784

Experiments (9)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - ALOX15 overexpression in healthy astrocytes should be protectiv	falsification	Neuroinflammation	0.400	0.50	mouse	proposed	$200,000
s:** - Compare uptake with/without magnetic particles using tight junc	falsification	Neurodegeneration	0.400	0.50	cell_line	proposed	$120,000
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
AAV Serotype Comparison for LRRK2 Knockdown in PD	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
Blood-Based Biomarker Panel for Early AD Detection	clinical	Alzheimer's Disease	0.400	0.50	cell_line	proposed	$220,000
Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur	validation	Neurodegeneration	0.400	0.50	cell_line	proposed	$130,000
Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown	validation	Parkinson's Disease	0.400	0.50	mouse	proposed	$280,000
Progranulin Replacement Therapy for FTD — Vector Development and Valid	clinical	ALS	0.400	0.50	human	proposed	$5,460,000

Related Papers (20)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies [PMID:40447280]	Russell CD, Goeldner-Thompson S, Smith E	J Infect Dis	2025	1
An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766]	Huang Q, Chan KY, Wu J, Botticello-Romer	Science	2024	1
Targeting the transferrin receptor to transport antisense oligonucleotides acros [PMID:39141703]	Barker SJ, Thayer MB, Kim C, Tatarakis D	Sci Transl Med	2024	1
Blood-brain barrier transport using a high affinity, brain-selective VNAR antibo [PMID:33241587]	Stocki P, Szary J, Rasmussen CLM, Demydc	FASEB J	2021	1
Transferrin receptor 1 in cancer: a new sight for cancer therapy. [PMID:30034931]	Shen Y, Li X, Dong D, Zhang B, Xue Y, Sh	American journal of cancer res	2018	1
Cadmium exposure is associated with impaired ovarian function: Potential role of [PMID:41548307]	["Li J", "Wang Y", "Huang Y", "Li N", "Z	Journal of hazardous materials	2026	0
A humanized transferrin receptor 1-transferrin model supports functional iron ho [PMID:41338456]	Yesiltepe M, Metkar S, Yin T, Chakrabort	The Journal of biological chem	2026	0
Early hypoxia-induced secretome remodeling reveals adaptive mechanisms and bioma [PMID:41699623]	Wu Q, Jiang Y, Peng L, Dang Y, You C, Li	Molecular brain	2026	0
MITF programs macrophage iron homeostasis to drive gut-liver inflammatory axis i [PMID:41832955]	Han D, Han L, Kang L, Liu J, Zhang N, Tu	Cell reports	2026	0
Ferrostatin-1 alleviates experimental cerebral malaria by regulating immune cell [PMID:41422632]	Yao S, Zhou X, Liao T, Yao C, Sun M, Gou	International journal for para	2025	0
Dietary Iron Deficiency in Adult Mice Increases Brain Uptake of High-Affinity, A [PMID:41299828]	Kostrikov S, Johnsen KB, Burkhart A, Hel	Journal of neurochemistry	2025	0
A covalent peptide-based lysosome-targeting protein degradation platform for can [PMID:39910101]	Xiao Y, He Z, Li W, Chen D, Niu X, Yang	Nature communications	2025	0
Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis. [PMID:38743190]	["Hu K", "Jiang P", "Hu J", "Song B", "H	Journal of bioenergetics and b	2024	0
Ferroptosis promotes valproate-induced liver steatosis in vitro and in vivo. [PMID:39147356]	["Yan X", "Ma L", "Chen X", "Ren J", "Zh	Food and chemical toxicology :	2024	0
TfR-conjugated nanoparticles achieve 50-fold increase in brain delivery vs free [PMID:synthetic_13]	Unknown	ACS Nano	2023	0
Specialized pro-resolving mediators reduce brain inflammation and amyloid pathol [PMID:synthetic_9]	Unknown	Nature Med	2023	0
TfR saturation limits uptake of targeting ligands at physiological transferrin c [PMID:synthetic_15]	Unknown	Mol Pharm	2022	0
Resolvin D1 promotes microglial phagocytosis and suppresses inflammatory cytokin [PMID:synthetic_11]	Unknown	J Neuroinflammation	2021	0
High-dose SPM analogs cause off-target immunosuppression in sepsis models [PMID:synthetic_14]	Unknown	Crit Care Med	2021	0
ALOX15 polymorphisms associated with Alzheimer's disease risk and age of onset [PMID:synthetic_12]	Unknown	Ann Neurol	2020	0

Debates (2)

Multi-agent debates referencing this entity

SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re

closed · Rounds: 4 · Score: 0.83 · 2026-04-06

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc

closed · Rounds: 4 · Score: 0.90 · 2026-04-03

TFRC

Understanding Entity Pages

Summary

Wiki Pages (3)

TFRC

TFRC Protein

Transferrin Receptor 1 (TFRC)

Pathway Diagram

Outgoing (182)

Incoming (199)

Targeting Hypotheses (2)

Mentioning Analyses (2)

Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)

Neuroinflammation resolution mechanisms and pro-resolving mediators

Experiments (9)

Related Papers (20)

Debates (2)

SPMs (resolvins, protectins, maresins) from omega-3s may promote inflammation re

What cell types are most vulnerable in Alzheimers Disease based on SEA-AD transc